-

Professor Chunyan Sun: Application of Peripheral Blood Circulating Plasma Cell Detection in Multiple Myeloma (MM) | The 15th Academic Conference of the Chinese Medical Association’s Experimental Diagnosis Hematology Branch and the First Academic Conference on Rare Blood Diseases
From March 23rd to 24th, 2024, the 15th Academic Conference of the Chinese Medical Association’s Experimental Diagnosis Hematology Branch and the First Academic Conference on Rare Blood Diseases, hosted by…
-

Professor Chengcheng Fu: The Current Status and Future Trends of CAR-T Therapy for Multiple Myeloma | The 7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunity Summit Forum
From March 2nd to 3rd, 2024, the “7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematologic Malignancies and Immunity Summit Forum,” hosted by the National Clinical Research Center for Blood Diseases at Peking University Institute of Hematology and Chinese Academy of Medical Sciences Peking Union Medical College Hospital, was successfully held in Beijing.…
-

EBMT Hot Review | Professor Depei Wu: PT-Cy Regimen for GVHD Prevention May Lead to T-Cell Diversity Deficiency, Significantly Impacting Efficacy and Safety
Graft-versus-host disease (GVHD) is one of the major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), exhibiting diverse clinical manifestations with prolonged course. Improper diagnosis and treatment can not only affect patients’ quality of life but also have a significant impact on long-term survival. With the continuous improvement of modern transplant technology, patients’ demand for…
-

EBMT China’s Voice | Professor Deyan Liu’s Team: Allogeneic Hematopoietic Stem Cell Transplantation Significantly Improves Survival Rates for Patients with Therapy-Related Myeloid Neoplasms
Therapy-related myeloid neoplasms (t-MN) are a distinct type of myeloid tumor that occur after cytotoxic or radiation therapy. In the 2022 WHO classification of hematopoietic and lymphoid tissue tumors, these were termed secondary myeloid neoplasms, including those related to cytotoxic treatment and genetic susceptibility. Compared to newly diagnosed AML, therapy-related AML (t-AML) has a poorer…
-

EBMT China’s Voice | Professors Ke Xiaoyan and Hu Kai’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year’s conference,…
-

Professor Yin Wu: Diagnosis and Treatment Evaluation of Multiple Myeloma: Examination and Application
Every March is the international “Myeloma Awareness Month”. In order to better serve patients with multiple myeloma, recently, the Hematology Department of Beijing Chaoyang Hospital, affiliated with Capital Medical University, held a series of activities for Multiple Myeloma Awareness Month. The aim is to enhance public awareness of multiple myeloma through a combination of online…
-

Professor Bing Han: Accessibility of new drugs will benefit more PNH patients | The 15th Experimental Hematology Conference and the First Rare Blood Disease Academic Conference
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by acquired gene mutations in hematopoietic stem cells, with complement-mediated intravascular hemolysis being its main pathological feature. The disease is…
